Posted by Michael Wonder on 10 Nov 2017
Agenda for 9 November TC meeting
7 November 2017 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of:
- Pentosan polysulphate sodium (Elmiron)
- Nusinersen sodium (Spinraza)
- Sarilumab (Kevzara)
- Carfilzomib (Kyprolis)
- Cenegermin (Oxervate)
- Regorafenib monohydrate (Stivarga)
